China Biologic Products Inc. (CBPO) Lowered to Hold at Zacks Investment Research
China Biologic Products Inc. (NASDAQ:CBPO) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Tuesday.
According to Zacks, “China Biologic Products, Inc., through its indirect majority-owned subsidiary, is principally engaged in the research, development, production, manufacturing and sale of plasma-based biopharmaceutical products to hospitals and other health care facilities in China. Its subsidiary, Shandong Taibang Biological Products Co. Ltd., operates from its manufacturing facility located in Taian City, Shandong Province. The Company’s principal products include its approved human albumin and immunoglobulin products. These human albumin products are mainly used to increase blood volume and its immunoglobulin products are used for the treatment and prevention of diseases. “
Other equities analysts have also issued research reports about the stock. Jefferies Group reaffirmed a “buy” rating and set a $136.00 target price on shares of China Biologic Products in a research report on Friday, July 22nd. Credit Suisse Group AG raised shares of China Biologic Products from a “neutral” rating to an “outperform” rating in a research report on Tuesday, July 5th.
Shares of China Biologic Products (NASDAQ:CBPO) traded down 2.51% during mid-day trading on Tuesday, reaching $120.09. 168,361 shares of the company traded hands. China Biologic Products has a 52-week low of $95.70 and a 52-week high of $144.29. The stock has a market capitalization of $3.23 billion, a PE ratio of 34.63 and a beta of 1.55. The stock’s 50 day moving average is $119.27 and its 200 day moving average is $117.24.
China Biologic Products (NASDAQ:CBPO) last released its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported $1.26 EPS for the quarter, beating the Zacks’ consensus estimate of $1.16 by $0.10. China Biologic Products had a net margin of 29.66% and a return on equity of 19.65%. The company had revenue of $91.40 million for the quarter, compared to analyst estimates of $87.60 million. During the same quarter last year, the firm posted $1.06 earnings per share. The company’s quarterly revenue was up 15.6% compared to the same quarter last year. On average, analysts anticipate that China Biologic Products will post $4.33 earnings per share for the current year.
In other China Biologic Products news, CFO Ming Yang sold 21,092 shares of the business’s stock in a transaction on Monday, August 15th. The shares were sold at an average price of $124.32, for a total value of $2,622,157.44. Following the sale, the chief financial officer now owns 24,782 shares of the company’s stock, valued at approximately $3,080,898.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Zhijing Cbpo Liu sold 1,968 shares of the business’s stock in a transaction on Monday, August 15th. The shares were sold at an average price of $124.32, for a total transaction of $244,661.76. The disclosure for this sale can be found here. Corporate insiders own 2.68% of the company’s stock.
A number of large investors have recently made changes to their positions in CBPO. Copper Rock Capital Partners LLC raised its stake in shares of China Biologic Products by 9.3% in the third quarter. Copper Rock Capital Partners LLC now owns 22,901 shares of the biopharmaceutical company’s stock valued at $2,834,000 after buying an additional 1,941 shares during the period. BNP Paribas Arbitrage SA raised its stake in shares of China Biologic Products by 3,357.5% in the third quarter. BNP Paribas Arbitrage SA now owns 1,383 shares of the biopharmaceutical company’s stock valued at $172,000 after buying an additional 1,343 shares during the period. Macquarie Group Ltd. acquired a new stake in shares of China Biologic Products during the second quarter valued at about $2,721,000. CI Investments Inc. raised its stake in shares of China Biologic Products by 13.1% in the second quarter. CI Investments Inc. now owns 65,700 shares of the biopharmaceutical company’s stock valued at $6,985,000 after buying an additional 7,600 shares during the period. Finally, Royal Bank of Canada acquired a new stake in shares of China Biologic Products during the second quarter valued at about $9,733,000. 71.71% of the stock is currently owned by hedge funds and other institutional investors.
About China Biologic Products
China Biologic Products, Inc (China Biologic) is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates in the manufacture and sales of human plasma products segment. It has a product portfolio with over 20 various dosage forms of plasma products and other biopharmaceutical products across over nine categories.
Receive News & Stock Ratings for China Biologic Products Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products Inc. and related stocks with our FREE daily email newsletter.